Kohima News Paper

Dyskinesia Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Dyskinesia Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

September 27
01:30 2022

“DelveInsight’s Dyskinesia Pipeline Insight 2022 report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Dyskinesia pipeline landscape”

 

It covers the Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dyskinesiatherapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Dyskinesia Pipeline Report

  • DelveInsight’s Dyskinesia Pipeline analysis depicts the space with 40+ active players working to develop 45+ pipeline therapies.
  • The Dyskinesia pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
  • Dyskinesia Pipeline Companies included Contera Pharma, VistaGen Therapeutics, Inc., Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, PharmaTher, Integrative Research Laboratories AB, Teva Branded Pharmaceutical, Luye Pharma Group, Ultragenyx Pharmaceutical Inc, IMAC holdings, Neurocrine Biosciences, Inc., PolyCore, Texas Biomedical Research Institute, ReCode Therapeutics, SOM Biotech, and many others.
  • Dyskinesia Pipeline Therapies included CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and many others.

 

To know more about the Dyskinesia Pipeline report, click here:- https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight

 

Dyskinesia Overview

Dyskinesia are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson’s itself. Rather, they are a complication from some Parkinson’s medications. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. Dyskinesia’s usually begin after a few years of treatment with levodopa and can often be alleviated by adjusting dopaminergic medications. Younger people with PD are thought to develop earlier motor fluctuations and dyskinesia’s in response to levodopa. Dyskinesia’s may be mild and non-bothersome, or they can be severe. Most people with Parkinson’s prefer to be “on” with some dyskinesia’s rather than “off” and unable to move well. However, for some people, dyskinesia’s can be severe enough that they interfere with normal functioning. The most common kind of dyskinesias are “peak dose.”

 

Dyskinesia Pipeline Insight Report

Dyskinesia Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyskinesia pipeline landscape is provided which includes the disease overview and Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Emerging Dyskinesia Drugs under Different Phases of Clinical Development Include:-

  • JM-010: Contera Pharma
  • NLX 112: Neurolixis
  • CPL 500036: Celon Pharma

 

DelveInsight’s Dyskinesia Pipeline Report covers around 45+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Download the Dyskinesia Pipeline Report to learn more about the emerging Dyskinesia emerging therapies at @ https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight

 

Dyskinesia Pipeline Therapeutic Analysis

There are approx. 40+ key companies which are developing therapies for Dyskinesia. The companies which have their Dyskinesia drug candidates in the most advanced stage, i.e. phase II include, Contera Pharma.

 

Dyskinesia Pipeline development activities

The Dyskinesia pipeline report provides insights into:

  • All of the companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Dyskinesia
  • Dyskinesia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Dyskinesia

The Dyskinesia Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Request for Sample PDF Report to know more about Dyskinesia drugs and therapies- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dyskinesia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dyskinesia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name : Company Name
  9. Mid Stage Products (Phase II)
  10. JM-010: Contera Pharma
  11. Early Stage Products (Phase I)
  12. Drug Name : Company Name
  13. Preclinical and Discovery Stage Products
  14. Drug Name : Company Name
  15. Inactive Products
  16. Dyskinesia Key Companies
  17. Dyskinesia Key Products
  18. Dyskinesia- Unmet Needs
  19. Dyskinesia- Market Drivers and Barriers
  20. Dyskinesia- Future Perspectives and Conclusion
  21. Dyskinesia Analyst Views
  22. Dyskinesia Key Companies
  23. Appendix

 

Download Sample PDF Report for Dyskinesia clinical trials advancements @ https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/